Navigation Links
GENova names Aaron Whiteman as CEO
Date:8/18/2009

NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

Mr. Whiteman, is a graduate of Oxford University and London School of Economics. He will provide GENova with his unique blend of exceptional sales, marketing, business and networking skills, combined with solid business management experience and the vision to marry novel products with new market opportunities. Mr. Whiteman has extensive experience in team building and negotiation. He has previously worked with companies such as Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and Biogen Idec (Nasdaq: BIIB).

Mr. Whiteman said, "I am excited to provide the executive leadership to take GENova to its next stage of growth in this crucial phase of commercializing GENova's technology in the marketplace."

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers and infectious disease. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.At present, GENova is rapidly building its portfolio of proprietary biotechnology. GENova's target market - cancer treatments - is the largest disease market, exploding at a 20% growth rate each year. GENova's treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). GENova has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: